Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 77 | SFEBES2021 | Next issue

Society for Endocrinology BES 2021

Edinburgh, United Kingdom
08 Nov 2021 - 10 Nov 2021

Card image cap
Join us in Edinburgh for the flagship event of the Society for Endocrinology

Early Careers and Plenary Orals

Clinical Endocrinology Trust Best Abstract Clinical

ea0077ec1.3 | Clinical Endocrinology Trust Best Abstract Clinical | SFEBES2021

Phase 3 and extension study of modified-release hydrocortisone in the treatment of congenital adrenal hyperplasia

Merke Deborah P , Mallappa Ashwini , Arlt Wiebke , De La Perriere Aude Brac , Hirschberg Angelica Linden , Juul Anders , Newell-Price John D C , Perry Colin Graham , Prete Alessandro , Rees Aled , Reisch Nicole , Stikkelbroeck Monica , Touraine Philippe A , Lewis Alexander , Maltby Kerry , Treasure Peter , Porter John , Ross Richard John M

Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes. We compared disease control in CAH adults treated with modified release hydrocortisone (MRHC, Chronocort®, Diurnal Ltd) versus standard glucocorticoid (GC).Methods: 6-month, Phase 3 study in 122 patients randomised to either MRHC twice daily or standard GC followed by safety extension study on MRHC. Patients had 24-hr 17...